APA (7th ed.) Citation

Lee, Y. J., Lee, Y., Park, J., Cho, H., Lim, M. C., Kim, M. K., . . . Lee, J. (2025). A phase II study of induction PD-1 blockade (nivolumab) in patients with surgically completely resectable mismatch repair deficient endometrial cancer (NIVEC). Journal of gynecologic oncology, 36(3), e35-8. https://doi.org/10.3802/jgo.2025.36.e35

Chicago Style (17th ed.) Citation

Lee, Yong Jae, Yoo-Young Lee, Jeong-Yeol Park, Hyun-Woong Cho, Myong Cheol Lim, Mi Kyung Kim, Jong-Min Lee, and Jung-Yun Lee. "A Phase II Study of Induction PD-1 Blockade (nivolumab) in Patients with Surgically Completely Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)." Journal of Gynecologic Oncology 36, no. 3 (2025): e35-8. https://doi.org/10.3802/jgo.2025.36.e35.

MLA (9th ed.) Citation

Lee, Yong Jae, et al. "A Phase II Study of Induction PD-1 Blockade (nivolumab) in Patients with Surgically Completely Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)." Journal of Gynecologic Oncology, vol. 36, no. 3, 2025, pp. e35-8, https://doi.org/10.3802/jgo.2025.36.e35.